Cargando…
Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
OBJECTIVE: To study the clinical effect of Zhengyuan capsule combined with neoadjuvant chemotherapy in the treatment of triple-negative breast cancer (TNBC). METHODS: From September 2014 to September 2017, 120 TNBC patients who underwent radical mastectomy in our hospital were randomly divided into...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152350/ https://www.ncbi.nlm.nih.gov/pubmed/35656462 http://dx.doi.org/10.1155/2022/1375724 |
_version_ | 1784717626029637632 |
---|---|
author | Zhang, Xiaoyu Li, Huixin Wu, Feng Sun, Dan Zhang, Hengle Jin, Lijun Kang, Xiaoning Wang, Zunyi |
author_facet | Zhang, Xiaoyu Li, Huixin Wu, Feng Sun, Dan Zhang, Hengle Jin, Lijun Kang, Xiaoning Wang, Zunyi |
author_sort | Zhang, Xiaoyu |
collection | PubMed |
description | OBJECTIVE: To study the clinical effect of Zhengyuan capsule combined with neoadjuvant chemotherapy in the treatment of triple-negative breast cancer (TNBC). METHODS: From September 2014 to September 2017, 120 TNBC patients who underwent radical mastectomy in our hospital were randomly divided into control group (n = 60) and observation group (n = 60). The short-term curative effect, the incidence of toxicity and side effects, and the score of quality of life of the patients were compared. Both recurrence and metastasis rates were also analyzed. RESULTS: The combined treatment of Zhengyuan capsule with neoadjuvant chemotherapy significantly improved the objective remission rate (70.00% in the observation group versus 40.00% in the control group) (P < 0.05). Moreover, this combined treatment significantly decreased the total incidence of side effects (35.00% versus 75.00%). Accordingly, the score of quality of life was also increased in patients treated with Zhengyuan capsule plus neoadjuvant chemotherapy (P < 0.05). Furthermore, supplementation of Zhengyuan capsule can significantly suppress both the recurrence and metastasis rate of TNBC in patients treated with neoadjuvant chemotherapy after radical mastectomy in following 3 years (30.00% versus 10.00%, P < 0.05). CONCLUSION: Zhengyuan capsule effectively improves the short-term curative effect, reduces the side effects of chemotherapy, and improves the quality of life of patients treated with neoadjuvant chemotherapy after radical mastectomy. More importantly, this combined treatment can also reduce the long-term recurrence and metastasis of TNBC. |
format | Online Article Text |
id | pubmed-9152350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-91523502022-06-01 Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Zhang, Xiaoyu Li, Huixin Wu, Feng Sun, Dan Zhang, Hengle Jin, Lijun Kang, Xiaoning Wang, Zunyi Evid Based Complement Alternat Med Research Article OBJECTIVE: To study the clinical effect of Zhengyuan capsule combined with neoadjuvant chemotherapy in the treatment of triple-negative breast cancer (TNBC). METHODS: From September 2014 to September 2017, 120 TNBC patients who underwent radical mastectomy in our hospital were randomly divided into control group (n = 60) and observation group (n = 60). The short-term curative effect, the incidence of toxicity and side effects, and the score of quality of life of the patients were compared. Both recurrence and metastasis rates were also analyzed. RESULTS: The combined treatment of Zhengyuan capsule with neoadjuvant chemotherapy significantly improved the objective remission rate (70.00% in the observation group versus 40.00% in the control group) (P < 0.05). Moreover, this combined treatment significantly decreased the total incidence of side effects (35.00% versus 75.00%). Accordingly, the score of quality of life was also increased in patients treated with Zhengyuan capsule plus neoadjuvant chemotherapy (P < 0.05). Furthermore, supplementation of Zhengyuan capsule can significantly suppress both the recurrence and metastasis rate of TNBC in patients treated with neoadjuvant chemotherapy after radical mastectomy in following 3 years (30.00% versus 10.00%, P < 0.05). CONCLUSION: Zhengyuan capsule effectively improves the short-term curative effect, reduces the side effects of chemotherapy, and improves the quality of life of patients treated with neoadjuvant chemotherapy after radical mastectomy. More importantly, this combined treatment can also reduce the long-term recurrence and metastasis of TNBC. Hindawi 2022-05-23 /pmc/articles/PMC9152350/ /pubmed/35656462 http://dx.doi.org/10.1155/2022/1375724 Text en Copyright © 2022 Xiaoyu Zhang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhang, Xiaoyu Li, Huixin Wu, Feng Sun, Dan Zhang, Hengle Jin, Lijun Kang, Xiaoning Wang, Zunyi Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
title | Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
title_full | Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
title_fullStr | Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
title_full_unstemmed | Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
title_short | Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
title_sort | clinical observation of zhengyuan capsule combined with neoadjuvant chemotherapy for triple-negative breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152350/ https://www.ncbi.nlm.nih.gov/pubmed/35656462 http://dx.doi.org/10.1155/2022/1375724 |
work_keys_str_mv | AT zhangxiaoyu clinicalobservationofzhengyuancapsulecombinedwithneoadjuvantchemotherapyfortriplenegativebreastcancer AT lihuixin clinicalobservationofzhengyuancapsulecombinedwithneoadjuvantchemotherapyfortriplenegativebreastcancer AT wufeng clinicalobservationofzhengyuancapsulecombinedwithneoadjuvantchemotherapyfortriplenegativebreastcancer AT sundan clinicalobservationofzhengyuancapsulecombinedwithneoadjuvantchemotherapyfortriplenegativebreastcancer AT zhanghengle clinicalobservationofzhengyuancapsulecombinedwithneoadjuvantchemotherapyfortriplenegativebreastcancer AT jinlijun clinicalobservationofzhengyuancapsulecombinedwithneoadjuvantchemotherapyfortriplenegativebreastcancer AT kangxiaoning clinicalobservationofzhengyuancapsulecombinedwithneoadjuvantchemotherapyfortriplenegativebreastcancer AT wangzunyi clinicalobservationofzhengyuancapsulecombinedwithneoadjuvantchemotherapyfortriplenegativebreastcancer |